Search results for "Clero"

showing 10 items of 2052 documents

One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?

2021

The recent ESC/EAS 2019 Guidelines for the management of dyslipidaemias are centred on the causal role of low density lipoprotein (LDL), or more generally apolipoprotein B (apoB)-containing lipoproteins, in atherosclerosis as an essential principle. Despite updated goals and recommendations, that have further highlighted the importance of a powerful reduction in LDL-C levels to reduce the individual CV risk, some challenges remain to be addressed in view of future guideline elaboration. In this review, we will summarize the new evidence from clinical trials since 2019 guideline release and discuss the possible challenges for the future.

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BControl (management)Guidelinechemistry.chemical_compoundRisk FactorsCardiovascular DiseasePrimary preventionCardiovascular disease DyslipidemiaInternal MedicineHumansMedicineIntensive care medicineDyslipidemiasSecondary preventionPrimary preventionbiologybusiness.industryCholesterolSecondary preventionLDL-C treatmentCholesterol LDLGuidelineAtherosclerosisClinical trialCholesterolchemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Risk Factors: AtherosclerosiHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessEuropean Journal of Internal Medicine
researchProduct

An Exploratory Look at Bicuspid Aortic Valve (Bav) Aortopathy: Focus on Molecular and Cellular Mechanisms

2019

Bicuspid aortic valve (BAV) is the most common congenital heart malformation. BAV patients are at increased risk for aortic valve disease (stenosis/regurgitation), infective endocarditis, thrombi formation and, in particular, aortic dilatation, aneurysm and dissection. This review aims at exploring the possible interplay among genetics, extracellular matrix remodeling, abnormal signaling pathways, oxidative stress and inflammation in contributing to BAV-associated aortopathy (BAV-A-A). Novel circulating biomarkers have been proposed as diagnostic tools able to improve risk stratification in BAV-A-A. However, to date, the precise molecular and cellular mechanisms that lead to BAV-A-A remain …

medicine.medical_specialtySettore MED/09 - Medicina InternaBicuspid aortic valveHeart malformationBicuspid aortic valve; atherosclerosisInflammationRegurgitation (circulation)030204 cardiovascular system & hematologymedicine.disease_cause03 medical and health sciences0302 clinical medicineBicuspid aortic valveAneurysmBicuspid Aortic Valve DiseaseInternal medicinemedicineHumans030212 general & internal medicinebusiness.industryHemodynamicsGeneral Medicinemedicine.diseaseVulnerable plaqueStenosisInfective endocarditisAortic ValveCardiologymedicine.symptomatherosclerosisbusinessCardiology and Cardiovascular MedicineBiomarkers
researchProduct

Clinical utility of novel biomarkers for cardiovascular disease risk stratification

2012

Over the past few decades, a number of coronary artery disease (CAD) and cardiovascular disease (CVD) risk factors have been identified. The predictive power of "conventional" risk factors have been validated by observational, prospective and intervention studies. Nevertheless, all attempts to exactly predict the individual risk for CAD have failed, biased by a large number of incorrectly risk-classified subjects. To improve cardiovascular (CV) risk prediction, a large number of genetic and/or non-genetic biomarkers have been discovered and tested against the "classical" risk factors for their power to predict CV risk. Only few of them had a significant improvement over the predictive model…

medicine.medical_specialtySettore MED/09 - Medicina InternaDiseaseIndividual riskRisk AssessmentCoronary artery diseaseInternal MedicinemedicineHumansRisk factorIntensive care medicinebusiness.industryBiomarkerCardiovascular riskAtherosclerosismedicine.diseaseIntervention studiesSurgeryCardiovascular DiseasesEmergency MedicineDisease riskPredictive powerObservational studybusinessPredictive powerBiomarkersInternal and Emergency Medicine
researchProduct

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiova…

2017

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal Supplements : Journal of the European Society of Cardiology
researchProduct

LDL size and subclasses in patients with abdominal aortic aneurysm

2009

Abstract Since the type of dyslipidemia in patients with abdominal aortic aneurysm (AAA) is still insufficiently defined, we measured plasma lipids and analyzed LDL size and subclasses by gradient gel electrophoresis in 30 male patients (69±6 years, BMI: 27±3) with newly diagnosed AAA and in 26 age- and BMI-matched male healthy controls. Patients with AAA had lower HDL-cholesterol ( p p =.0002) and smaller LDL size ( p p =.0210) in relation to controls. Multivariate analysis also showed that small LDL size was independently associated with the presence of AAA ( p =.0350). Increased levels of small, dense LDL may therefore represent a common feature in patients with AAA.

medicine.medical_specialtySmall dense ldl610 Medicine & healthmacromolecular substancesDense LDLSmallLDL sizeGastroenterology2705 Cardiology and Cardiovascular MedicineAortic aneurysmInternal medicinePlasma lipidsmedicineIn patientcardiovascular diseasesbusiness.industrymedicine.diseaseAbdominal aortic aneurysmEndocrinologymedicine.anatomical_structureMale patientcardiovascular systemAbdominal aortic aneurysmAbdomenlipids (amino acids peptides and proteins)10029 Clinic and Policlinic for Internal MedicineaterosclerosiCardiology and Cardiovascular MedicinebusinessDyslipidemia
researchProduct

Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?

2005

The term "lipid triad" or "atherogenic lipoprotein phenotype" has been introduced to describe a common form of dyslipidemia, characterized by three lipid abnormalities: increased plasma triglyceride levels, decreased HDL-cholesterol concentrations and the presence of small, dense LDL particles. It has been suggested that the clinical importance of the atherogenic lipoprotein phenotype probably exceeds that of LDL-cholesterol, because many more patients with coronary artery disease are found to have this trait than hypercholesterolaemia. There is a body of evidence that therapies effective against plasma HDL-cholesterol and triglycerides are associated with a strong reduction of cardiovascul…

medicine.medical_specialtySmall dense ldlBiologyCoronary artery diseaseCardiovascular preventionInternal medicineInternal MedicinemedicineHumansNational Cholesterol Education ProgramDyslipidemiasHypolipidemic AgentsLDL HDL triglycerides preventionBiochemistry (medical)LDL Particle SizeTriad (anatomy)Atherogenic lipoprotein phenotypemedicine.diseaseAtherosclerosisLipoproteins LDLEndocrinologymedicine.anatomical_structureCardiovascular Diseaseslipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineDyslipidemiaJournal of atherosclerosis and thrombosis
researchProduct

Update on the role of the atherogenic lipoprotein phenotype in cardiovascular prevention

2009

Higher plasma triglyceride levels and decreased HDL-cholesterol concentrations are usually accompanied by the presence of small, dense LDL in the so-called lipid triad or ‘atherogenic lipoprotein phenotype’. This phenotype is highly atherogenic and its prevalence may suggest an even higher overall burden of atherosclerotic disease as compared with that associated with hypercholesterolemia. As stated by the National Cholesterol Education Program Adult Treatment Panel III, there is evidence suggesting each component of this lipid triad is individually atherogenic. However, the relative contribution of each component cannot be easily determined. Therefore, it has been suggested to consider th…

medicine.medical_specialtySmall dense ldlbusiness.industryAtherosclerotic diseaseAtherogenic lipoprotein phenotype dense LDL gradient gel electrophoresis HDL-cholesterol triglyceridesAtherogenic lipoprotein phenotypePhenotypeEndocrinologyCardiovascular preventionPlasma triglycerideInternal medicineMolecular MedicineMedicinelipids (amino acids peptides and proteins)Risk factorCardiology and Cardiovascular MedicinebusinessNational Cholesterol Education ProgramFuture Cardiology
researchProduct

Should we measure routinely the LDL peak particle size?

2004

Low density lipoproteins (LDL) do not show in humans a normal distribution and comprise two different main fractions: large, buoyant (phenotype pattern A) and small, dense (phenotype pattern B) particles, that differ not only in size and density but also in physicochemical composition, metabolic behaviour and atherogenicity. The prevalence of small, dense LDL changes with age (30-35% in adult men, 5-10% in men <20 years and in pre-menopausal women, 15-25% in postmenopausal women) and is genetically influenced, with a heritability ranging from 35% to 45%. Small, dense LDL correlate negatively with plasma HDL levels and positively with plasma triglyceride levels and are associated with the me…

medicine.medical_specialtySmall dense LDLAcute myocardial infarctionCoronary artery diseaseRisk FactorsDiabetes mellitusInternal medicineDiabetes MellitusmedicineHumansMyocardial infarctionParticle SizeRisk factorNational Cholesterol Education ProgramTriglyceridesMetabolic Syndromebusiness.industryVascular diseasePreventionmedicine.diseaseLipoproteins LDLCoronary heart diseasePhenotypeCardiovascular DiseasesAtherosclerosiCirculatory systemCardiologylipids (amino acids peptides and proteins)Metabolic syndromeLipoproteins HDLCardiology and Cardiovascular Medicinebusiness
researchProduct

Spontaneous anterior cervicothoracic spinal epidural hematoma extending to clivus in SARS-CoV-2 infection

2021

Background: The treatment of spontaneous spinal epidural hematomas (SSEHs), depending on the lesion size and myeloradicular involvement, can be surgical or conservative. Here, we present a 55-year-old patient who sustained a SSEH several months following a systemic SARS-CoV-2 infection. Case Description: A 55-year-old immunocompromised female (i.e., history 17 years ago of Hodgkin’s lymphoma, nodular sclerosis variant) recently developed a SARS-CoV-2 infection treated with nonsteroidal anti-inflammatory agents. She then reported the sudden onset of cervicodorsalgia after a slight cervical flexion/extension maneuver. The brain and cervicothoracic spine MRI studies documented a clival anteri…

medicine.medical_specialtySpinalSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.medical_treatmentCase ReportLesion03 medical and health sciences0302 clinical medicineHematomaClivusNodular sclerosismedicineReduction (orthopedic surgery)Hematomabusiness.industrySpontaneousCOVID-19medicine.diseaseSurgeryLymphomamedicine.anatomical_structure030220 oncology & carcinogenesisEpiduralSurgeryNeurology (clinical)medicine.symptombusinessSpinal epidural hematoma030217 neurology & neurosurgerySurgical Neurology International
researchProduct

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart diseas…

2013

AIMS: The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD).METHODS AND RESULTS: Of the theoretical estimated prevalence of 1/500 for heterozygous FH, &lt;1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD. Based on prev…

medicine.medical_specialtyStatinAtherosclerosis; Cardiovascular disease; Cholesterol; Coronary heart disease; Low-density lipoproteinSettore MED/09 - Medicina Internamedicine.drug_classPopulationCHILDRENFamilial hypercholesterolemiaBile acid bindingCOST-EFFECTIVENESS ANALYSIS030204 cardiovascular system & hematologyLDL-CHOLESTEROLDIAGNOSIS03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicineMANAGEMENT030212 general & internal medicineeducationHealth aging / healthy living Cardiovascular diseases [IGMD 5]Alirocumabeducation.field_of_studyCYTOKINE PATTERN CHANGEbusiness.industryLow-density lipoproteinmedicine.diseaseAtherosclerosisCardiovascular diseaseLomitapideDENSITY-LIPOPROTEIN APHERESIS3. Good healthASSOCIATION EXPERT PANELCoronary heart diseaseEndocrinologyCholesterolchemistryCARDIOVASCULAR-DISEASEAtherosclerosiCardiology and Cardiovascular MedicinebusinessSTATIN TREATMENTmedicine.drugEuropean Heart Journal
researchProduct